Skip to content
2000
Volume 10, Issue 4
  • ISSN: 1874-4672
  • E-ISSN: 1874-4702

Abstract

It is noteworthy that thirty three years of efforts in corticotropin releasing factor (CRF) research by academia and the pharmaceutical industry resulted in several thousand papers and patents, yet little progress has been made to identify and market diagnostic or therapeutic CRF peptides and small molecule ligands. We document the potential relevance of CRF peptide antagonists to reinvigorate stress/anxiety affected “anatomy systems” in order to boost their efficacy.

Loading

Article metrics loading...

/content/journals/cmp/10.2174/1874467210666170110112914
2017-11-01
2025-05-17
Loading full text...

Full text loading...

/content/journals/cmp/10.2174/1874467210666170110112914
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test